Shanghai Xuhui Central Hospital
Shanghai, Shanghai Municipality, 200031, China
NCT Number: NCT04989829
This is a one-arm, fixed-sequence study to compare the pharmacokinetic profiles of SHR6390 in absence and presence of prior administration of proton pump inhibitor Omeprazole. The increased gastric pH achieved by the treatment with multiple doses of Omeprazole might affect the absorption process of SHR6390.
Looking for future studies?
Notify Me18 year–45 year
All sexes
Interventional
Phase 1
Shanghai, Shanghai Municipality, 200031, China
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
SHR6390 tablet single dose、Omeprazol single dose.
Time frame: from Day1 to Day7after the first dose and from Day17 to Day23 after the second dose
Maximum observed serum concentration (Cmax) for SHR6390 after Single dose.
Time frame: from Day1 to Day7after the first dose and from Day17 to Day23 after the second dose
Area under the plasma concentration versus time curve (AUC0-t) for SHR6390 after Single dose
Time frame: from Day1 to Day7after the first dose and from Day17 to Day23 after the second dose
Area under the plasma concentration versus time curve (AUC0-∞) for SHR6390 after Single dose
Time frame: from Day1 to Day7after the first dose and from Day17 to Day23 after the second dose
Time to maximum observed serum concentration (Tmax) for SHR6390 after Single dose
Time frame: from Day1 to Day7after the first dose and from Day17 to Day23 after the second dose
Time to elimination half-life (T1/2) for SHR6390 after Single dose.[Time Frame
Time frame: from Day1 to Day7after the first dose and from Day17 to Day23 after the second dose
Apparent oral clearance (CL/F) for SHR6390 after Single dose
Time frame: from Day1 to Day7after the first dose and from Day17 to Day23 after the second dose
Apparent Volume of Distribution (Vz/F) SHR6390 after Single dose
Time frame: from Day1 to Day30 after the first dose
Jiangsu HengRui Medicine Co., Ltd.
Industry
A Single-centre, One-arm, Open-label, Fixed-sequence Study to Evaluate the Effect of Omeprazole on the Pharmacokinetics of SHR6390 in Healthy Male and Female Subjects
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04374877
Adenocarcinoma, Advanced Solid Tumor
Duarte, California, United States
View Trial DetailsNCT06470763
Advanced Solid Tumor
Detroit, Michigan, United States
View Trial DetailsNCT06403436
Adult Disease, Adult Solid Tumor
Nashville, Tennessee, United States
View Trial DetailsNCT03239145
Adnexal Diseases, Advanced Solid Tumor
Boston, Massachusetts, United States
View Trial Details